Advertisement
Advertisement
U.S. markets close in 4 hours 36 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Insig AI Plc (INSG.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
32.000.00 (0.00%)
As of 02:57PM BST. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close32.00
Open32.50
Bid30.00 x N/A
Ask34.00 x N/A
Day's Range32.50 - 32.50
52 Week Range19.06 - 86.90
Volume50,000
Avg. Volume161,234
Market Cap33.816M
Beta (5Y Monthly)N/A
PE Ratio (TTM)64.00
EPS (TTM)0.50
Earnings DateDec 22, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for INSG.L

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Simply Wall St.

      Can Insig AI Plc's (LON:INSG) ROE Continue To Surpass The Industry Average?

      While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

    • GlobeNewswire

      Bio-Path Granted Key Mechanism of Action U.S. Patent for BP1003

      Provides Protection and Highlights Novelty of BP1003 to Inhibit STAT3 Expression in a Variety of Difficult to Treat CancersHOUSTON, June 22, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that the United States Patent and Trademark Office has granted a new patent relating to the Company’s BP1003 p

    Advertisement
    Advertisement